ClinicalTrials.Veeva

Menu
G

Gastroenterology Associates of Central Georgia, LLC | Gastrointestinal Research and Clinical Trial Center of Georgia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
Upadacitinib
Vedolizumab
CP-690,550
ABT-494
Etrolizumab
Filgotinib
Budesonide
Vonoprazan
Adalimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 69 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab Matching Placebo
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with p...

Enrolling
Moderately to Severely Active Ulcerative Colitis
Drug: Placebo
Drug: RO7790121
Locations recently updated

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Active, not recruiting
Crohn's Disease (CD)
Drug: ABT-494

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting
Ulcerative Colitis
Drug: Filgotinib
Drug: Placebo

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Drug: Survodutide
Drug: Placebo

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Enrolling
Bowel; Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

Enrolling
Esophageal Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Risankizumab
Drug: Ustekinumab

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Active, not recruiting
Ulcerative Colitis
Drug: ABBV-668
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting...

Enrolling
Crohn's Disease
Drug: Risankizumab
Drug: Lutikizumab

Trial sponsors

AbbVie logo
Roche logo
Pfizer logo
Bausch Health logo
Shire logo
Takeda logo
Gilead Sciences logo
M
Phathom Pharmaceuticals logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems